UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a ...

T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and ...

Indonesia’s Health Ministry confirmed that nine people who tested positive during a whole-body counter (WBC) examination for ...

Blood-based biomarkers, including neutrophil-to-lymphocyte ratio and circulating tumor DNA, may improve treatment response ...

ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX ...

A monocyte mitochondrial superoxide cutoff accurately stratified short-term survival risk in hepatocellular carcinoma.

Results from the phase 2 study C-145-03 (NCT03083873) suggest the role of autologous tumor-infiltrating lymphocyte (TIL) therapy in treating and stabilizing recurrent and or metastatic head and neck ...

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...